🔗 Share this article

While the United States undertakes sweeping revisions to its immunization recommendations, an unexpected name has surfaced unexpectedly: Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning coronavirus vaccinations throughout the pandemic and has focused upon potential deaths following Covid immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities were set to reveal major changes to the pediatric immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US out of step with a large portion of the global community with no evidence for improved outcomes. This reveal has been pushed back until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this calendar year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a society with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Expertise

Dr. Høeg has no apparent track record in pharmaceutical research, approval processes or leadership, which has been typical for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that prior appointees who led the center have had.”

CDER has an enormous portfolio at the agency, the former commissioner emphasized.

“Many people just focuses on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and all of those must be supervised,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the position, which oversees more than 5,000 employees. “It is a massive administrative position, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on incorrect premises”.

“This background is consistent with the duties of her position,” the official said, noting the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious one-day therapy clearance system that reportedly concerned her predecessors. “How are these drugs being selected for this voucher program? Who makes the decisions?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed regulations of most medications, with the exception of shots.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a more established, if problematic, history, critics observe. She published a analysis using unverified public submissions to assess the incidence of heart inflammation following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the current administration included changing guidelines for new vaccines and halting “unnecessary” vaccines, she remarked after the election on a podcast. At the FDA, Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the data in a highly misleading, untruthful way,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined other skeptics, {like|